Table 2.

Effect of I3C on metastasis of breast cancer cells through targeting Cdc25A degradation in a xenograft mouse model

Group	Cancer cells injecteda	No. of mice	I3Cb	% of mice with lung metastasis	No. of dead micec	No. of tumor nodules per lung (meand ± SD)	% reduction in tumor nodule no.e	P value
1	Control	15	−	73	7	15 ± 3
2	Control	15	+	20	2	6 ± 1	60	<0.01
3	Cdc25AWT	15	−	100	14	30 ± 4
4	Cdc25AWT	15	+	27	3	11 ± 2	63	<0.01
5	Cdc25AS82A	15	−	100	14	31 ± 4
6	Cdc25AS82A	15	+	33	4	12 ± 3	61	<0.01
7	Cdc25AS124A	15	−	100	14	34 ± 4
8	Cdc25AS124A	15	+	93	13	32 ± 3	<6	>0.5

^aControl, MDA-MB-231 breast cancer cells without exogenous Cdc25A; Cdc25A^WT, cells with exogenous wild-type Cdc25A; Cdc25A^S82A, cells with exogenous mutation Cdc25A^S82A; Cdc25A^S124A, cells with exogenous mutation Cdc25A^S124A.

^bThe concentration of I3C was 1.5 mg/day/mouse. +, treated; −, untreated.

^cThe number of dead mice during the study period (10 weeks).

^dMean for the mice with lung metastasis and counting tumor nodule numbers per lung in four sections as described in Materials and Methods.

^eRelative percentage of the group with I3C treatment versus that without I3C treatment among the mice for each breast cancer cell type.